Please assess the completion status of the following clinical trial:

Trial Title: Histologic Assessment of the Difference Between 18F-2-fluoro-2-deoxy_D-glucose Positron Emission Mammography(PEM) and Magnetic Resonance Imaging (MRI) of the Breast

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Female patients with recently diagnosed invasive or in situ breast cancer by core needle biopsy or FNA (confirmed at MSKCC) prior to enrollment.~* Patients planning treatment with mastectomy at MSKCC.~* Patients 21 years old or older.~* Patients who had or are having a breast MRI within 30 days or less of PEM.~* Patients who had or are having a digital mammogram.~Exclusion Criteria:~* Patients who are pregnant or breast feeding.~* Patients with prior radiation therapy or endocrine therapy.~* Patients who had a prior lumpectomy.~* Patients who are diabetic.~* Patients with moderate to end stage kidney disease.~* Patients who have a contraindication to MRI (i.e. pacemaker, metallic implants, etc).

- Gender: FEMALE
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- MRI and PEM scans (Type: EXPERIMENTAL): All consenting patients who are to have staging breast MRI, will be offered 18FDG PEM (Positron Emission Mammography) within 30 days. If the patient had a previous breast MRI that was done within 30 days at an outside institution, this MRI can be used if a radiologist determines that it is an adequate study. The surgery date will not be affected by the additional PEM evaluation. All imaging will be done and reviewed by MSKCC breast imagers. MRI and PEM findings suggestive of malignancy will be prospectively recorded in both the ipsilateral and contralateral breast.

Based on this trial design, predict the completion outcome and termination type (if applicable).